Herceptin "Dear Doctor" Letter To Emphasize Cardiac Risk
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech is reviewing language with FDA to advise of cardiotoxicity risk as it prepares to submit trastuzumab for treatment of adjuvant breast cancer. The firm reports that there have been multiple inquiries to the medical communication group for information on the cardiac monitoring protocol used in the adjuvant trials.
You may also be interested in...
Genentech “Dear Doctor” Letter Suggests Herceptin Cardiotoxicity Risk Factors
Age and left ventricular function following chemotherapy may identify patients at greatest risk for cardiac dysfunction, the company says.
Genentech “Dear Doctor” Letter Suggests Herceptin Cardiotoxicity Risk Factors
Age and left ventricular function following chemotherapy may identify patients at greatest risk for cardiac dysfunction, the company says.
Genentech Plans Herceptin Early-Stage Breast Cancer Submission
Genentech is planning a supplemental BLA for Herceptin (trastuzumab) for adjuvant treatment of early stage breast cancer. Much-lauded Phase III data at American Society of Clinical Oncology meeting show significant reduction in disease recurrence and overall survival improvement of 49% at four years.